ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Epidemiologic methods"

  • Abstract Number: 262 • 2016 ACR/ARHP Annual Meeting

    Seasonal Variation in Incidence of Sarcoidosis: A Population-Based Study 1976-2013

    Patompong Ungprasert1, Cynthia S. Crowson2 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN

    Seasonal Variation in Incidence of Sarcoidosis: A Population-Based Study 1976-2013 Background/Purpose:   Sarcoidosis is a multi-systemic disorder of unknown etiology. Studies of seasonal and regional…
  • Abstract Number: 1419 • 2016 ACR/ARHP Annual Meeting

    Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients

    Hervé Devilliers1, Meenakshi Jolly2, Maxime Samson3, Bernard Bonnotte4, Francois Maurier5, Pascal Sève6, Nadine Magy-Bertrand7, Denis Wahl8, Jean-Loup Pennaforte9, Thierry Martin10, Olivier Aumaître11, Gilles Blaison12, Philip Bielefeld13, Alexis Mathian14, Christine Binquet15 and Zahir Amoura14, 1Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 2Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, 3Dijon University Hospital, Dijon, France, 4Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, 6Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 7CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, 8CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, 9Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, 10Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, 11Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, 12Internal medicine departement, Colmar Hospital, Colmar, France, 13Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, 14Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 15INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France

    Background/Purpose: To assess validity and reliability of French LupusPRO in France. Methods: After cross-cultural adaptation and harmonization for France, the LupusPRO was administered along with…
  • Abstract Number: 3203 • 2016 ACR/ARHP Annual Meeting

    Analysis of Efficacy and Safety of Cyclophosphamide in Juvenile Dermatomyositis Using a Large National UK Cohort

    Claire Deakin1, Raquel Campanilho-Marques2, Stefania Simou3, Elena Moraitis4, Eleanor Pullenayegum5,6, Lucy R Wedderburn4,7,8, Clarissa Pilkington9 and Juvenile Dermatomyositis Research Group (JDRG), 1Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, 2Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, 3Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, 4Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, 5Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, 6Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 7Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 8Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 9Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

    Background/Purpose:  Cyclophosphamide (CYC) has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the efficacy of…
  • Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting

    Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study

    Sarah Dyball1 and Marwan Bukhari2, 1University Hospital South Manchester, Manchester, United Kingdom, 2Royal Lancaster Infirmary, Lancaster, United Kingdom

    Background/Purpose:   Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…
  • Abstract Number: 1505 • 2016 ACR/ARHP Annual Meeting

    Trends in Hospitalizations for Infections in US Patients with Rheumatoid Arthritis, 1993-2013

    Sadao Jinno1, Na Lu2,3, S. Reza Jafarzadeh4 and Maureen Dubreuil3,5, 1Rheumatology, Boston University School of Medicine, Boston, MA, 2Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 4Medicine, Washington University School of Medicine, St Louis, MO, 5Rheumatology, Boston VA HealthCare System, Boston, MA

    Background/Purpose: With the increasing uptake of RA treatments that confer infection risk, an increase in the rates of infection hospitalizations among RA patients is expected,…
  • Abstract Number: 407 • 2016 ACR/ARHP Annual Meeting

    Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA

    Stephanie J.W.Shoop1,2, Kimme L. Hyrich3,4, Suzanne M.M. Verstappen4, Wendy Thomson5,6, Janet E. McDonagh7 and CAPS, 1The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 2Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 3Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 5Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, 6NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 7Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom

    Background/Purpose: It is unclear which tool should measure functional ability in adolescents with JIA. The proxy-completed Childhood Health Assessment Questionnaire (P-CHAQ) is completed on the…
  • Abstract Number: 1519 • 2016 ACR/ARHP Annual Meeting

    How Much, and When, Does Autoimmune Thyroid Disease Increase the Risk of RA, and Does RA-Onset Impact the Risk of Autoimmune Thyroid Disease?

    Kristin Waldenlind1, Saedis Saevarsdottir1, Camilla Bengtsson2 and Johan Askling1, 1Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Environmental medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Autoimmune thyroid disease (AITD) is one of the most common autoimmune diseases, and occurs more often than expected in patients with Rheumatoid Arthritis (RA).…
  • Abstract Number: 693 • 2016 ACR/ARHP Annual Meeting

    The Prevalence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis

    Maren C. Karreman1,2, Jolanda J. Luime3, Johanna M.W. Hazes2 and Angelique E.A.M. Weel1, 1Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 2Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands

    Background/Purpose: Inflammatory Bowel Disease (IBD) is a chronic disease that affects up to 0.5% of the population, comprising both Crohn’s Disease (CD) and ulcerative colitis…
  • Abstract Number: 1705 • 2016 ACR/ARHP Annual Meeting

    The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis

    Lauren Harter1, Daniel Shin2, Joshua F. Baker3, Junko Takeshita2, Thorvardur Love4,5, Joel Gelfand6 and Alexis Ogdie7, 1Medicine, University of Pittsburgh, Pittsburgh, PA, 2University of Pennsylvania, Philadelphia, PA, 3Rheumatology, University of Pennsylvania, Philadelphia, PA, 4Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 5Landspitali University Hospital, Reykjavík, Iceland, 6University of Pennsylvania Health System , Philadelphia, PA, 7Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture…
  • Abstract Number: 836 • 2016 ACR/ARHP Annual Meeting

    Comprehensive Characterization of Calcinosis in a Multicenter International Cohort of Patients with Systemic Sclerosis

    Antonia Valenzuela1,2, Jessica K. Gordon3, Tatiana Sofia Rodriguez-Reyna4, Susanna Proudman5,6, Murray Baron7, Monique Hinchcliff8, Dinesh Khanna9, Amber Young10, Flavia V. Castelino11, Sara R. Schoenfeld12, Virginia D. Steen13, David Fiorentino14 and Lorinda Chung15, 1Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 2Stanford University School of Medicine, Stanford, CA, 3Rheumatology, Hospital for Special Surgery, New York, NY, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 5Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 6Discipline of Medicine, University of Adelaide, Adelaide, Australia, 7Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, 8Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 9University of Michigan, Ann Arbor, MI, 10Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 11Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 12Rheumatology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 13Rheumatology, Georgetown University Medical Center, Washington, DC, 14Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, 15Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) affecting one quarter of patients. Repetitive trauma may be involved in the pathogenesis of…
  • Abstract Number: 1936 • 2016 ACR/ARHP Annual Meeting

    Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study

    Patompong Ungprasert1, Cynthia S. Crowson2, Rodrigo Cartin-Ceba3, James A. Garrity4, Wendy M. Smith5, Ulrich Specks6, Eric L. Matteson1 and Ashima Makol7, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN, 3Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, 4Ophthalmology, Mayo Clinic, Rochester, MN, 5Department of Ophthalmology, Mayo Clinic, Rochester, MN, 6Mayo Clinic, Rochester, MN, 7Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

    Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is…
  • Abstract Number: 870 • 2016 ACR/ARHP Annual Meeting

    Contemporary Prevalence Estimates for Giant Cell Arteritis and Polymyalgia Rheumatica, 2015

    Cynthia S. Crowson1 and Eric L. Matteson2, 1Health Sciences Research, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose:  There are no estimates of the prevalence of giant cell arteritis (GCA) or polymyalgia rheumatic (PMR) in a United States population in the current…
  • Abstract Number: 2016 • 2016 ACR/ARHP Annual Meeting

    Esophageal Disease in Systemic Sclerosis: Does Heritability Play a Role?

    Latifa Fakoya1, Kathryn Peterson2, Andrew Gawron2, Jathine Wong3, Mary Beth Scholand4, Allen D. Sawitzke5 and Tracy M. Frech6,7, 1Internal Medicine/Rheumatology, University of Utah, Salt Lake City, UT, 2Internal Medicine/Gastroenterology, University of Utah, Salt Lake City, UT, 3University of Utah, Salt Lake, UT, 4University of Utah, Salt Lake City, UT, 5Rheumatology, Univ of Utah, Salt Lake City, UT, 6Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, 7Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT

    Background/Purpose: Systemic sclerosis (SSc) associated gastroesophageal reflux disease (GERD) can cause symptoms of dysphagia and heartburn, and is associated with esophagitis, stricture, Barrett’s esophagus, and…
  • Abstract Number: 877 • 2016 ACR/ARHP Annual Meeting

    Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis

    Patompong Ungprasert1, Matthew J. Koster2, Kenneth J. Warrington3 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, 3Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN

    Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-analysis Background/Purpose: Several chronic inflammatory disorders, such as rheumatoid arthritis and…
  • Abstract Number: 2026 • 2016 ACR/ARHP Annual Meeting

    Are Adult Trajectories of Weight over a Lifetime Linked to Foot Problems Years Later?

    Alyssa B. Dufour1, Elena Losina2, Hylton B. Menz3, Michael P. Lavalley4 and Marian T. Hannan5, 1Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, 2Orthopaedics, Brigham & Women's Hospital, Boston, MA, 3Musculoskeletal Research Centre, La Trobe University, Bundoora, VIC, Australia, 4Biostatistics, Boston University School of Public Health, Boston, MA, 5Institute for Aging Research, Hebrew SL & Harvard Med School, Boston, MA

    Background/Purpose: Obesity and foot problems are common in older adults and associated with many negative health outcomes. Better understanding of the consequences of patterns of…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology